-

Limbix Named to CB Insights Digital Health 150 List

Company recognized for achievements in digital therapeutics on list of most innovative digital startups

SAN FRANCISCO--(BUSINESS WIRE)--Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, was named to CB Insights Digital Health 150 List, which recognizes the most promising private digital health companies in the world. This year’s Digital Health 150 List was unveiled during CB Insights annual Future of Health event. Companies represented on the 2021 list include startups working on data integration and analytics, hybrid virtual/in-person care, digital therapeutics, clinical intelligence, and more.

In October, Limbix launched SparkRx, the first digital therapeutic for adolescents with symptoms of depression. The SparkRx program is based on core principles of cognitive behavioral therapy, with a focus on behavioral activation, and is delivered to patients via smartphone app. Limbix also recently announced positive results from a clinical trial of SparkRx, which demonstrated a statistically significant reduction in depression symptoms, compared to an active control, for users who completed the program as recommended.

“Limbix is passionate about building digital therapeutics that support providers and improve access to mental health treatments for adolescents,” said Benjamin Lewis, chief executive officer of Limbix. “It has been an incredible year of growth in digital health and we are very proud to be recognized by CB Insights, alongside other incredible and innovative companies that seek to improve healthcare outcomes.”

CB Insights compiled the Digital Health 150 List from a pool of more than 11,000 companies. They were chosen based on several factors, including data submitted by the companies, company business models and momentum in the market, and Mosaic scores– CB Insights proprietary algorithm that measures the overall health and growth potential of private companies.

View the complete list of Most Innovative Digital Health Startups.

Learn more about the severity and prevalence of mental health concerns and depression in young adults.

About Limbix

Limbix is a prescription digital therapeutic company passionate about creating mental health treatments for adolescents. The Limbix team is uniquely suited to develop prescription digital therapeutics, as its diverse team of clinicians, product designers, researchers, and engineers understand the value of pairing clinical expertise with technological innovation. Their first digital therapeutic, SparkRx by Limbix, is available for licensed healthcare professionals to offer to patients nationwide.

For more information about Limbix and SparkRx, please visit limbix.com and SparkRx.com.

Social Media:
https://twitter.com/LimbixHealth
https://www.linkedin.com/company/limbix-health/
https://www.facebook.com/limbix.inc

Contacts

Liz Boten
Canale Communications for Limbix
Liz.boten@canalecomm.com
720.219.5107

CB Insights
press@cbinsights.com

Limbix


Release Versions

Contacts

Liz Boten
Canale Communications for Limbix
Liz.boten@canalecomm.com
720.219.5107

CB Insights
press@cbinsights.com

Social Media Profiles
More News From Limbix

Limbix Raises $15 Million in Series A2 Financing

SAN FRANCISCO--(BUSINESS WIRE)--Today, Limbix, a prescription digital therapeutic company developing treatments for adolescent mental health disorders, announced it has raised $15 million in Series A2 financing from both existing and new investors, bringing total funding to date to $31 million. The round was led by GSR Ventures, with participation from existing investors Digital Garage, Storm Ventures, Bixink and DN Capital. The round also includes investments from Korean Investment Partners, E...

Limbix Presents Data Demonstrating Treatment with SparkRx Digital Therapeutic Results in Clinically Meaningful Reductions in Depressive Symptoms in Adolescents

SAN FRANCISCO--(BUSINESS WIRE)--Today, Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, announced positive results from a virtual randomized controlled trial of SparkRx, the company’s digital therapeutic for adolescents with symptoms of depression. For participants that completed the program as recommended (n = 83), SparkRx led to a statistically significant reduction in depression symptoms compared to an active control app (p = 0.023) and...

Limbix Launches First Digital Therapeutic for Adolescents with Symptoms of Depression

SAN FRANCISCO--(BUSINESS WIRE)--Today, Limbix, a prescription digital therapeutic company developing mental health treatments for adolescents, announced the launch of SparkRx, the first evidence-based digital therapeutic for teens and young adults experiencing symptoms of depression. SparkRx is rooted in cognitive behavioral therapy, a therapeutic modality proven to assist with the symptoms of depression and other mental health disorders. SparkRx is an adjunct treatment for teens and young adul...
Back to Newsroom